Connecticut's cannabis retailers recorded $290 million in sales for 2025, a slight decline from the previous year's $293 million, even as December hit the highest monthly total since recreational legalization. State data reveals this downturn amid stiff competition from neighboring Massachusetts, where lower prices draw shoppers across the border. The trend underscores how taxes and market dynamics shape consumer choices in the young adult-use industry.
Tax Burden Pushes Customers Across State Lines
Connecticut imposes three taxes on cannabis purchases: a 6.35 percent state sales tax, a 3 percent local tax, and a THC-based levy adding 10 to 15 percent. Massachusetts applies a single cannabis tax atop the product price, resulting in lower overall costs. Erik Davidson, a Massachusetts resident, called Connecticut's system "kind of crazy" compared to his state's simpler structure. Benjamin Zachs, chief operating officer at Fine Fettle, noted that 15 to 20 percent of customers at the company's West Springfield, Massachusetts, location hail from Connecticut, with border towns feeling the heaviest impact.
Industry Expansion Meets Persistent Challenges
Adult-use cannabis gained approval in Connecticut in 2021, with retail stores opening a year later. Today, 61 licensed retailers operate statewide, including 29 hybrids approved for both medical and recreational sales. A recent state law expands hybrid eligibility, prompting conversions. Fine Fettle begins hybrid operations at its locations this week to broaden access, as Zachs explained: the push focuses on medical options amid recreational growth. Sales volume at local dispensaries directly funds host communities, tying retailer performance to municipal revenues.
Implications for Policy and Local Economies
The sales dip signals vulnerabilities in Connecticut's model four years post-legalization. Cheaper out-of-state options erode market share, potentially slowing tax revenue growth that supports schools, infrastructure, and public services. Retailers adapt through hybrid models to retain customers seeking medical discounts or variety, but price competitiveness remains key. As the industry matures, lawmakers face pressure to reassess tax structures to stem cross-border leakage and bolster domestic sales.
